ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,122Medicare Part D Prescriptions Filled, Including Refills

Rank: 40 out of 559

$420K Total Retail Price of All Prescriptions

Rank: 58 out of 559

493 Patients Receiving at Least One Drug in Part D
78%Patients 65 Years and Older
51% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 493 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

17% of this provider’s 493 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 7,008 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$46 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LEVOTHYROXINE SODIUM 544 463 1 2
LISINOPRIL 422 365 2 1
METFORMIN HCL 318 238 3 5
AMLODIPINE BESYLATE 285 278 4 6
OMEPRAZOLE 269 200 5 4
GABAPENTIN 261 181 6 9
HYDROCODONE-ACETAMINOPHEN 255 194 S3 7 7
SIMVASTATIN 221 181 8 3
METOPROLOL TARTRATE 217 174 9 12
ALENDRONATE SODIUM 197 191 10 13
LISINOPRIL-HYDROCHLOROTHIAZIDE 196 145 11 18
HYDROCHLOROTHIAZIDE 192 136 12 8
PRAVASTATIN SODIUM 173 121 13 35
GEMFIBROZIL 160 99 14 71
METOPROLOL SUCCINATE 159 140 15 16
SERTRALINE HCL 145 131 16 19
OXYCODONE HCL-ACETAMINOPHEN 125 47 S2 17 70
CARISOPRODOL 125 43 R 17 73
ZOLPIDEM TARTRATE 123 92 19 17
FUROSEMIDE 120 110 20 11
ATORVASTATIN CALCIUM 89 73 21 20
LOVASTATIN 88 75 22 10
PROAIR HFA 80 57 23 29
WARFARIN SODIUM 80 74 23 24
TRAZODONE HCL 80 54 23 28
POTASSIUM CHLORIDE 67 66 26 23
ATENOLOL 66 65 27 15
CLONIDINE HCL 63 46 28 68
MORPHINE SULFATE ER 63 20 S2 28 63
GLIPIZIDE 63 53 28 31
TAMSULOSIN HCL 62 52 31 25
CLOPIDOGREL 62 59 31 51
TERAZOSIN HCL 61 52 33 82
CYMBALTA 59 19 34 78
OXYCODONE-ACETAMINOPHEN 59 42 S2 34 44
BENAZEPRIL HCL 57 46 36 85
DIOVAN 57 57 36 55
SPIRONOLACTONE 57 35 36 74
MIRTAZAPINE 57 37 36 61
PAROXETINE HCL 56 41 40 48
ADVAIR DISKUS 55 41 41 46
CARVEDILOL 55 53 41 38
DONEPEZIL HCL 54 54 43 36
FLUTICASONE PROPIONATE 54 44 43 22
AVODART 52 52 45 124
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 30, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.